IE
INMB icon

Israel Englander’s INmune Bio INMB Stock Holding History

Israel Englander’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$116K – 6227
2025
Q2 		$116K Buy
+50,000
New +$367K ﹤0.01% 5497

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Israel Englander's INMB Position: Q2 2026 in Review

Israel Englander opened a new position in INmune Bio (INMB) in Q2 2026: 159,559 shares worth $260K. The stake represents ﹤0.01% of the portfolio and ranks #5185 among its holdings. This is a return to the name: Israel Englander previously reported a position in INMB as recently as Q2 2025.

Israel Englander first reported a position in INMB in Q1 2021 and has held it in 15 quarters since. The position peaked at $2.4M in Q3 2021. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Israel Englander held 159,559 shares of INmune Bio worth $260K as of Q2 2026.
  • INmune Bio was a new Israel Englander position in Q2 2026.
  • INmune Bio made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5185 holding.
  • Israel Englander first reported a position in INmune Bio in Q1 2021 and has held it in 15 quarters since.
  • Israel Englander's INmune Bio position peaked at $2.4M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.